This article is more than 5 years old. Information may no longer be current.
Androgen deprivation therapy may increase diabetes risk
Click Here to Manage Email Alerts
Men with prostate cancer treated with long-term and short-term androgen deprivation therapy are more likely to develop diabetes then men who are not treated with the therapy, according to a meta-analysis in the Journal of Diabetes Investigation.
Huimin Wang, MD, of Nankai Clinical School of Tianjin Medical University in China, and colleagues analyzed data from eight studies conducted through 2014 that included 157,588 patients diagnosed with prostate cancer (four large-scale cohort studies; four cross-sectional studies). Patients were either treated with various types of androgen deprivation therapy (ADT; n = 65,695) or served as controls not treated with ADT (n = 91,893). Only studies examining diabetes outcomes as the endpoint were included.
Among the ADT patients, 7,136 went on to develop diabetes (approximately 10.9%), whereas 6,987 of non-ADT patients developed diabetes (approximately 7.6%). Researchers found that the pooled incidence of diabetes was 39% higher in the ADT groups (RR = 1.39; 95% CI, 1.27-1.53).
In an analysis of two studies comparing different types of ADT, researchers found diabetes was significantly associated with gonadotropin-releasing hormone alone (RR = 1.45; 95% CI, 1.36-1.54), gonadotropin-releasing hormone plus oral antiandrogen (RR = 1.4; 95% CI, 1.01-1.93) and orchiectomy (RR = 1.34; 95% CI, 1.2-1.5), but not with antiandrogen monotherapy (RR = 1.33; 95% CI, 0.75-2.36).
Diabetes was significantly associated with long-duration ADT of 6 months or more (RR = 1.43; 95% CI, 1.22-1.68), and was slightly associated with shorter-duration ADT (RR=1.29; 95% CI, 1.12-1.49).
One study also found that men receiving ADT had a higher prevalence of abdominal hyperglycemia, according to researchers. – by Regina Schaffer
Disclosure: The researchers report no relevant financial disclosures.
Click Here to Manage Email Alerts